Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

71.03
+0.62500.89%
Volume:316.91K
Turnover:22.37M
Market Cap:3.95B
PE:6.40
High:71.03
Open:70.33
Low:70.15
Close:70.40
52wk High:74.59
52wk Low:59.47
Shares:55.60M
Float Shares:55.60M
Volume Ratio:0.74
T/O Rate:0.57%
Dividend:0.81
Dividend Rate:1.14%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.41
PE(LYR):23.22

Loading ...

US FDA Approves AbbVie's Drug for Parkinson's Disease

Reuters
·
Sep 26

US FDA - Approves Juvmo (Tavapadon) for Parkinson’s Disease in Adults on Sept 25, 2026

THOMSON REUTERS
·
Sep 26

Ifinatamab Deruxtecan Biologics License Application for Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

Reuters
·
Sep 26

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 26

Eli Lilly Gets Expanded Label Approval from FDA for Alopecia Drug

Dow Jones
·
Sep 26

FDA Approves Lilly's Olumiant (Baricitinib) for Pediatric Patients 12 Years of Age and Older with Severe Alopecia Areata

THOMSON REUTERS
·
Sep 26

Merck, Daiichi Sankyo Withdraw US Application for Lung Cancer Drug

Reuters
·
Sep 26

Merck, Daiichi Sankyo voluntarily withdraw BLA for ifinatamab deruxtecan

TIPRANKS
·
Sep 26

Merck & Co - Daiichi Sankyo and Merck Withdraw Bla for Ifinatamab Deruxtecan in Es-Sclc in U.S.

THOMSON REUTERS
·
Sep 26

Merck & Co - Withdrawal Based on FDA Discussions; Phase 2 Data Do not Satisfy Approval Requirements

THOMSON REUTERS
·
Sep 26

Merck & Co - Patient Enrollment Continues in Ideate-Lung02 Phase 3 Trial for Ifinatamab Deruxtecan

THOMSON REUTERS
·
Sep 26

Merck & Co - Two Additional Phase 3 Trials Underway for Ifinatamab Deruxtecan in Crpc and Escc

THOMSON REUTERS
·
Sep 26

UnitedHealth Announces R$ 0.115248942 Dividend Per Unit for 3Q 2026

Reuters
·
Sep 26

Exchange-Traded Funds Rise US Equities Advance After Midday

MT Newswires Live
·
Sep 26

ADARx Pharmaceuticals Shares Soar in NASDAQ Debut After Upsized IPO

Reuters
·
Sep 26

Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case

MT Newswires Live
·
Sep 26

Innovation is Driving a New Bull Market in Biotech. 16 Ways to Play It, from Our Roundtable Experts.

Dow Jones
·
Sep 25

Exchange-Traded Funds, Equity Futures up Pre-Bell Friday as Treasury Yields Rise, Oil Prices Fall

MT Newswires Live
·
Sep 25

Sector Update: Healthcare Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Sep 25

Johnson & Johnson Says Tremfya Significantly Improves Axial Psoriatic Arthritis Symptoms in Phase 4 Study

MT Newswires Live
·
Sep 25